Abstract
While the sympathetic nervous system is essential for vital physiological functions, overactivity in certain pathological states causes significant morbidity and mortality. Adrenergic antagonists block the action of catecholamines on the adrenergic receptors. Phenoxybenzamine and phentolamine are non-specific alpha blockers while prazosin and its derivatives block the alpha 1 receptors with some specificity. Alpha receptor blockade is particularly helpful in patients with pheochromocytoma and other conditions where the blood pressure is dangerously high. Localization of subtypes of alpha receptors on the bladder outlet makes it possible to relieve urinary retention of benign prostatic hyperplasia while more specific treatments can work. Beta blockers have become extremely useful drugs especially because of the favorable actions in patients with certain cardiovascular diseases. Nonselective beta blockers have been rapidly replaced by more specific and useful beta 1 receptor blockers. Propranolol is the prototypical nonselective beta blocker. Due to its adverse action on the lipid profile and the bronchi, it has been replaced by generations of beta 1 specific receptor blockers some of which are still in active development. Proper understanding of the physiological alterations caused by adrenergic blockers is essential for the effective clinical management while minimizing adverse drug reactions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Bibliography
Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS et al (2008) Pheochromocytoma: current approaches and future directions. Oncologist 13(7):779–793
Dézsi CA, Szentes V (2017) The real role of β-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs 17(5):361–373
DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D’Ascenzo F, Cerrato E et al (2015) β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart 2(1):e000230
Farrugia FA, Martikos G, Tzanetis P, Charalampopoulos A, Misiakos E, Zavras N et al (2017) Pheochromocytoma, diagnosis and treatment: review of the literature. Endocr Regul 51(3):168–181
Foody JM, Farrell MH, Krumholz HM (2002) β-Blocker therapy in heart failure: scientific review. JAMA 287(7):883–889
Frishman WH (1988) Beta-adrenergic receptor blockers. Adverse effects and drug interactions. Hypertension. https://www.ahajournals.org/doi/abs/10.1161/01.HYP.11.3_Pt_2.II21
Kim EH, Larson JA, Andriole GL (2016) Management of benign prostatic hyperplasia. Annu Rev Med 67(1):137–151
Pedersen ME, Cockcroft JR (2006) The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 8(4):279–286
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Paul, A. (2021). Adrenergic Antagonists. In: Paul, A., Anandabaskar, N., Mathaiyan, J., Raj, G.M. (eds) Introduction to Basics of Pharmacology and Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-33-6009-9_4
Download citation
DOI: https://doi.org/10.1007/978-981-33-6009-9_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-33-6008-2
Online ISBN: 978-981-33-6009-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)